What Oregon Therapeutics does

Oregon Therapeutics is a privately held, pre-clinical stage biotechnology company developing XCE853, a first-in-class targeted oncology therapy based on inhibition of protein disulfide isomerase (PDI). The company's scientific platform, branded as Onco-Metabolism, exploits the metabolic vulnerabilities of certain cancers through a novel mechanism of action distinct from conventional chemotherapy and existing targeted therapies. Priority indications are ovarian cancer and advanced pancreatic cancer, with potential expansion into liver, prostate, head & neck, and orphan cancers. The company was founded with French operations headquartered in Paris (3 rue du Colonel Moll, 75017) and a US presence in Boonton, New Jersey, supported by a four-person executive team with deep pharmaceutical R&D credentials and a distinguished scientific advisory board spanning institutions such as Institut Curie, Gustave Roussy, and the University of Birmingham.

The company's underlying technology is centered on a proprietary small-molecule PDI inhibitor developed through classical medicinal chemistry, with a scientific foundation traceable to peer-reviewed publications from 2012 through 2023 covering ovarian, breast, neuroblastoma, head & neck, multiple myeloma, acute myeloid leukemia, lung adenocarcinoma, and other indications. The stated near-term objective is to advance XCE853 into clinical phase within 2 years. The company has not disclosed patents, granted regulatory designations, or named licensing partners in the available data.

Oregon Therapeutics' go-to-market model is enterprise pharma licensing and co-development. As a pre-clinical asset company, it intends to monetize XCE853 through upfront payments, R&D funding, milestone payments, and royalties negotiated with pharmaceutical or biotech partners that will drive late-stage clinical development and commercialization. The company is currently pre-revenue with no disclosed customers or signed licensing agreements. Its only disclosed funding event is a 2015 AGORANOV investment, and there is no public record of subsequent institutional funding rounds or partnership economics.

Name

Oregon Therapeutics

Legal name

Oregon Therapeutics

Website

https://oregon-therapeutics.com

Company type

Private

Founded year

2014

Operating status

Operating

Headcount range

1–10 employees

Short description

Oregon Therapeutics is a pre-clinical French biotech developing XCE853, a first-in-class protein disulfide isomerase inhibitor for ovarian and pancreatic cancer. It pursues a pharma licensing and co-development business model, targeting clinical phase entry within two years.

Ownership category

akta.pro rank

Product category

Oncology Therapeutics

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Pharmaceutical Preparations (2834), Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation) (HLAAAIAI)

Keywords

• Oncology drug development
• Cancer therapeutics
• Metabolic inhibitors
• Preclinical biotech
• Pharma licensing

Headquarters

HQ city

Paris

HQ country

France

HQ region

Europe

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations

Revenue model

1. Licensing and Co-development Deals: As a pre-clinical stage company, Oregon Therapeutics' primary revenue model is licensing its XCE853 compound and onco-metabolism platform to pharmaceutical partners via co-development agreements, milestone payments, and royalties. Revenue is expected to be generated through upfront payments, R&D funding, clinical/regulatory milestones, and commercial royalties upon partner-driven development and commercialization.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

Core offering

Oregon Therapeutics is a pre-clinical stage biotech developing XCE853, a first-in-class and best-in-class targeted oncology therapy based on the inhibition of Protein Disulfide Isomerase (PDI). The company exploits the metabolic vulnerability of certain cancers, with priority indications in ovarian cancer and advanced pancreatic cancer, and potential additional indications in liver, prostate, head & neck, and orphan cancers. The stated objective is to bring XCE853 into Clinical Phase within 2 years.

Product overview

Oregon Therapeutics is developing a single core product pipeline centered on its Onco-Metabolism platform. The lead candidate is XCE853, a disruptive targeted therapy classified as both 'First in Class' and 'Best in Class' in oncology, operating via inhibition of protein disulfide isomerase. Priority indications are Ovarian Cancer and advanced Pancreatic Cancer, with potential additional indications in Liver, Prostate, Head & Neck, and certain Orphan Cancers. The company aims to advance XCE853 into Clinical Phase within 2 years.

Differentiator

Problem solved

Functional benefit

Brands

• XCE853: First-in-class and best-in-class targeted therapy in oncology based on inhibition of protein disulfide isomerase for the treatment of cancer, with priority indications in Ovarian Cancer and advanced Pancreatic Cancer.

Products and services

• XCE853 XCE853 is a disruptive targeted therapy classified as 'First in Class' and 'Best in Class' in oncology, based on an innovative and unique mechanism of action: Inhibition of Protein Disulfide Isomerase (PDI). Priority indications are Ovarian Cancer and advanced Pancreatic Cancer, with potential additional indications in Liver, Prostate, Head & Neck, and Orphan Cancers. The product is being developed for out-licensing or co-development with pharmaceutical partners.

Quantifiable outcome

• Bringing XCE853 into Clinical Phase for the treatment of Cancer within 2 years

Segments1 record

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature1 record

Scale indicators4 records

Recent moves5 records

Expansion highlights4 records

Direct peers

• Calithera Biosciences: Calithera developed small-molecule inhibitors targeting cancer metabolism (glutaminase inhibitor telaglenastat), pursuing a similar pharma-licensing and partnership-driven model for metabolic enzyme targets. Like Oregon Therapeutics, Calithera was a small-cap clinical-stage biotech focused on first-in-class metabolic targets in oncology.
• Erasca: Erasca is a precision oncology biotech developing small-molecule therapies targeting the MAPK pathway, with multiple programs and a partnership-driven GTM. Comparable as a small-to-mid biotech in the novel-mechanism oncology space pursuing licensing economics.
• Kronos Bio:
• Repare Therapeutics: Repare develops synthetic-lethality-based precision oncology drugs, pursuing first-in-class mechanisms in partnership with pharma (notably Bristol-Myers Squibb). Repare's SNIPRx platform and licensing-first approach parallels Oregon Therapeutics' plan to license XCE853 to larger pharma partners for clinical development.
• Foghorn Therapeutics: Foghorn is a clinical-stage biotech targeting chromatin biology in cancer with first-in-class small molecules, pursuing both internal development and pharma partnerships. Comparable as a small-cap biotech whose value sits in a novel mechanism-of-action platform with licensing optionality.
• Black Diamond Therapeutics: Black Diamond develops precision oncology medicines targeting allosteric mutations, with a similar small-team, asset-focused structure and a pipeline of first-in-class kinase inhibitors. Comparable as a small-cap clinical-stage biotech pursuing novel mechanism partnerships.
• PMV Pharmaceuticals: PMV Pharma develops first-in-class p53 reactivators for cancer, a single-asset-focused company with a novel mechanism targeting a specific cancer vulnerability. Comparable structure as a small biotech whose entire value proposition rests on a single first-in-class oncology asset.

Broad incumbents

• Agios Pharmaceuticals: Agios pioneered cancer metabolism drug development with IDH1/IDH2 inhibitors (TIBSOVO, IDHIFA) and is the most established public reference point for the cancer metabolism therapeutic strategy that Oregon Therapeutics' PDI platform pursues. Despite being much larger and now commercially focused, Agios' early-stage profile (pre-approval metabolism platform) is the closest comparable thesis for Oregon Therapeutics' licensing model.
• Forma Therapeutics: Forma developed small molecules targeting cancer metabolism and DNA damage response pathways, with a strong licensing/out-licensing model (e.g., partnerships with Boehringer Ingelheim, Forma-1 deals). Acquired by Novo Nordisk in 2022 for $1.1B, Forma represents the upper bound of a successful exit trajectory for a metabolic-focused oncology biotech of Oregon Therapeutics' profile.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat2 records

Key risks6 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/oregontherapeutics/about

Revenue estimate

Valuation estimate

Number of profiles

Profiles4 records

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Oregon Therapeutics